ReportWire

Tag: American Public Health Association

  • Oklahoma Could Be Stepping Into A Huge Marijuana Mess

    [ad_1]

    Oklahoma could be stepping into a huge marijuana mess as the governor targets the booming cannabis market.

    Oklahoma is no stranger to political firestorms. From fierce school funding battles to headline-grabbing budget fights over Medicaid expansion, the Sooner State has been rocked by dramatic clashes between lawmakers and voters. Now, another tempest is brewing—this one green, and potentially explosive. As Oklahoma’s medical marijuana industry boomed into one of the nation’s most lucrative markets, the governor’s office has signaled it might be time to slam the brakes, setting the stage of Oklahoma could be stepping in a huge marijuana mess.

    RELATED: Texas Works to Save Its Hemp Beverage Industry

    Since voters overwhelmingly approved State Question 788 in 2018, Oklahoma’s medical marijuana market has exploded into a significant economic force. In 2024 alone, dispensaries sold more than $715 million in medical cannabis products, generating roughly $82 million in tax revenue for the state through excise and sales taxes. Over the life of the program, revenue figures from licensing fees, excise taxes and sales tax contributions have added up to hundreds of millions of dollars funneled into state coffers, with education, substance abuse programs, and general funds all tapping into the proceeds.

    Health advocates and researchers point out medical cannabis isn’t just a cash crop. Numerous public health organizations—including the American Public Health Association, American College of Physicians and the Society of Cannabis Clinicians—have acknowledged cannabis can offer therapeutic value for patients with chronic pain, nausea and other debilitating conditions. A 1988 Drug Enforcement Administration administrative law judge concluded “marijuana, in its natural form, is one of the safest therapeutically active substances known to man,” and many physicians support its use in certain medical contexts.

    That backdrop makes Gov. Kevin Stitt’s recent push to revisit the state’s medical marijuana law all the more dramatic. Stitt has publicly questioned whether Oklahoma’s cannabis market has spiraled out of control, arguing there are now “more dispensaries than pharmacies” and linking the industry to broader public safety concerns. His call to scale back—or even shut down—the legal market has ignited fierce debate in the Capitol and across the state.

    Oklahoma Attorney General Gentner Drummond echoed the governor’s misgivings about how the program was initially implemented, describing it as “truly the Wild West.” But he also warned dismantling the program would likely trigger massive financial consequences. According to Drummond, the state could face obligations to reimburse hundreds of license-holders for investments made under the existing law, because repealing or undermining the program could be seen as an unlawful “taking.”

    RELATED: Is CBD Next On The Fed’s Hit List

    For business owners, farmers, tankful dispensary operators and investors who poured capital into cultivation facilities, retail locations, processing equipment and jobs in hundreds of small communities, the warning rings loud and clear. While precise data on total private investment in Oklahoma’s cannabis sector is hard to pin down, economic analyses have projected billions in sales and tax revenue under expanded legalization scenarios.

    As the Legislature and voters prepare for what could be one of the most contentious ballot battles in recent memory, Oklahoma finds itself at a crossroads. Will the state preserve a medical marijuana program supporters call a lifeline for patients and a boon for local economies? Or will it heed the governor’s calls to shut it down and face the political and financial fallout? For now, the drama is just beginning—and in Oklahoma, that means the stakes couldn’t be higher.

    [ad_2]

    Anthony Washington

    Source link

  • Evidence About Burning Mouth Syndrome And Cannabinoids

    [ad_1]

    Evidence About Burning Mouth Syndrome And Cannabinoids shows cannabis may ease pain through CBD’s nerve-calming effects.

    If you mouth on fire frequently?  There is evidence about Burning Mouth Syndrome and cannabinoids. It is a weird, stubborn condition: people feel a persistent burning, tingling or scalding pain in the mouth with little or no visible signs. For many sufferers, the pain is daily and annoying enough to wreck sleep, mood and social meals — so new options are getting attention, including cannabis-based therapies. But before you reach for an edible or CBD oil, here’s what the research actually shows.

    RELATED: 5 Ways Microdosing Cannabis Can Boost Work Performance

    Short version about help with Burning Mouth Syndrome (BMS). there is encouraging, early evidence cannabinoids — particularly CBD-dominant or topical cannabis extracts — might reduce neuropathic oral pain for some people. A small, open-label pilot found cannabis sativa oil reduced symptoms in people with primary BMS, suggesting a signal worth studying in larger trials. That study didn’t prove a cure, but it’s the kind of clinical pilot which pushes the field forward.

    Photo by LeslieLauren/Getty Images

    Why cannabinoids could plausibly help, BMS is often considered a neuropathic pain disorder (a problem with how nerves signal pain). Cannabinoids act on the endocannabinoid system, which plays a role in modulating pain, inflammation and stress — all relevant to BMS. Broader reviews of cannabinoids for chronic and neuropathic pain report moderate benefit in some neuropathic conditions, which supports the idea targeted cannabis-based treatments might be useful for mouth pain too.

    One attractive idea is using topical or intra-oral CBD formulations (drops, rinses, or oil applied to the mucosa) to get local effects without strong psychoactive side effects. Emerging reviews and early trials suggest intraoral CBD or cannabis-containing mouthwashes can reduce inflammation, pain, and even change oral microbiota in some small studies — but these findings are preliminary and product formulations vary widely. If dryness (xerostomia) is an issue — a common BMS complaint — be cautious: some cannabinoid products and delivery methods can affect salivation differently.

    RELATED: Boomer And Gen Z Consume Marijuana For Similar Reasons

    High-quality randomized controlled trials for cannabis specifically in BMS are still limited. Systematic reviews of BMS treatments note while several options can help some patients, consistent, large-scale evidence is lacking — and the same is true for cannabinoids in this specific condition. That means clinicians and patients must balance promising pilot data with uncertainty and potential side effects.

    A few practical takeaways

    • If considering cannabis for BMS, prioritize CBD-dominant or topical formulations and avoid high-dose THC until you know how you react.

    • Talk with your dentist/oral medicine specialist first — rule out nutritional deficiencies, meds, or infections mimicking BMS.

    • Expect a trial-and-error approach: some patients report meaningful relief; others don’t. A 2023 patient survey also found many people with neuropathic pain reported symptom improvement with cannabis, but self-report data has limits.

    Bottom line: cannabis is a promising avenue for some people with BMS, especially CBD/topical approaches, but evidence is early. If you’re curious, involve your clinician, start low, and track outcomes — the science is moving, but not finished.

    [ad_2]

    Amy Hansen

    Source link

  • Study Reveals Stance By Physicians And Public About Cannabis

    [ad_1]

    New research has been done on support for marijuana legalization – and it is surprising

    The numbers are in, and they tell a story America’s been building toward for decades. A new study reveals stance by physicians and the public about cannabis. The MRI-Simmons 2025 National Cannabis Study reveals use, interest, and acceptance are now part of everyday American life. What began as a counterculture experiment has matured into a mainstream market—and a movement reshaping everything from medicine to espresso martinis.

    RELATED: 5 Ways Microdosing Cannabis Can Boost Work Performance

    Once seen as taboo, cannabis is now embraced by a broad cross-section of the country. Millennials and Gen Z lead the charge, but even boomers are catching up. The study shows a steep climb in the number of Americans who say they’ve tried or regularly use cannabis products, with sharp rises in interest in CBD, microdosing, and low-dose edibles designed for relaxation and wellness.

    The shift in attitude coincides with a historic change in federal policy. After more than fifty years as a Schedule I drug—a category reserved for substances with “no accepted medical use”—cannabis is finally on track for rescheduling. Federal agencies under the Biden administration have proposed moving it to Schedule III, recognizing its legitimate medical potential and easing research and tax barriers.  The industry is waiting for the federal government to make a move as the have suggested.

    The decision is backed by a growing chorus in the medical community. The American Medical Association, American College of Physicians, and American Public Health Association all support more research access and medically guided legalization. For the first time, major medical institutions are signaling prohibition is outdated, unscientific, and harmful to patients.

    Polls now show nearly nine out of ten Americans support legal cannabis in some form. Even in conservative regions, medical use enjoys overwhelming approval. MRI-Simmons data finds public curiosity has evolved into cultural adoption—especially among wellness-oriented consumers who see cannabis as part of a balanced lifestyle rather than a rebellious act.

    The change is having ripple effects across industries, especially in alcohol. Beer sales have flattened as younger drinkers swap bar nights for low-dose cannabis drinks or CBD-infused mocktails. Wine and spirits are pivoting fast—introducing zero-proof lines and “cannabis-inspired” beverages to stay relevant. The alcohol industry, once a distant observer, is now studying the cannabis consumer closely.

    RELATED: Boomer And Gen Z Consume Marijuana For Similar Reasons

    As cannabis moves from stigmatized to standardized, the conversation has matured. It’s less about getting high and more about how people choose to relax, recover, and reconnect.

    The MRI-Simmons 2025 study doesn’t just track consumer data—it captures a cultural turning point. Cannabis is now part of the American mainstream, supported by science, normalized by policy, and embraced by the public.

    The only question left is how fast the rest of the system will catch up.

    [ad_2]

    Amy Hansen

    Source link